Diaceutics (LON:DXRX) Hits New 1-Year Low – Here’s Why

Diaceutics PLC (LON:DXRX) shares hit a new 52-week low on Tuesday . The company traded as low as GBX 125 and last traded at GBX 127, with a volume of 224054 shares traded. The stock had previously closed at GBX 128.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group reaffirmed a “buy” rating and set a GBX 215 price target on shares of Diaceutics in a research note on Wednesday. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of GBX 215.

Diaceutics Stock Up 4.5%

The firm has a fifty day simple moving average of GBX 142.78 and a 200-day simple moving average of GBX 153.38. The company has a market capitalization of £116.79 million, a PE ratio of 1,254.55 and a beta of 0.89. The company has a debt-to-equity ratio of 2.85, a quick ratio of 9.92 and a current ratio of 3.43.

Diaceutics (LON:DXRX) last posted its quarterly earnings results on Tuesday, May 26th. The company reported GBX 11 earnings per share (EPS) for the quarter. Diaceutics had a net margin of 0.25% and a return on equity of 0.25%. The firm had revenue of GBX 3,844 million for the quarter. Equities research analysts anticipate that Diaceutics PLC will post 1.0107919 EPS for the current fiscal year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.